lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS Registry

21 Pages Posted: 10 Mar 2021

See all articles by Tim Spelman

Tim Spelman

Karolinska Institutet - Department of Clinical Neuroscience

Lars Forsberg

Swedish MS Registry - Department of Clinical Neuroscience

Kyla McKay

Karolinska Institutet

Anna Glaser

Karolinska Institutet

Jan Hillert

Karolinska Institutet - Department of Clinical Neuroscience

More...

Abstract

Background: The primary objective of this study was to analyse the association between multiple sclerosis (MS) disease modifying therapy (DMT) exposure and subsequent hospitalisation in patients infected with COVID-19.

Methods: Data were extracted on the 18th January 2021 from the Swedish MS Registry, which collates nationwide, prospectively-collected clinical, demographic and, from March 2020 onwards, Covid-19-related information  (including diagnostics and need of health care including needs of hospitalization, intensive care and ventilation) among persons with MS. Associations between MS DMT exposure and COVID-19 hospitalisation were analysed using univariable and multivariable clustered logistic regression, where the models were clustered on the individual patients to control for patients contributing multiple COVID-19 episodes. Propensity score based inverse probability of treatment weighting (IPTW) approach was used to adjust for confounders.

Findings: As of 18th January 2021, a total of 476 reported COVID-19 cases had been recorded in MS patients in the Swedish MS registry. Of these, 292 (61.3%) had confirmed COVID-19. The mean (SD) age at infection was 44.0 years (11.6). Of the 292 confirmed infections 68 (23.2%) required hospitalisation. A total of 49 of the 164 confirmed COVID-19 patients on rituximab at baseline (29.9%) required hospitalisation, compared to a rate of 12.7% for all other DMTs combined. Rituximab in confirmed COVID-19 patients was associated with 2.95 times the weighted odds of hospitalisation relative to treatment with any other alternate DMT combined (Odds Ratio 2.95; 95% CI 1.48-5.87). The risk of severe COVID-19 increased with duration of rituximab treatment with a yearly Odds Ratio of 1.24 (95% CI 1.04-1.48).

Interpretation: Rituximab treatment, known to increase the risk of severe infections in general, also confers such a risk for MS patients with COVID-19, in comparison with other MS DMTs.

Funding: This study was supported by the Swedish Research Council and the Swedish Brain Foundation.

Declaration of Interest: TS has received compensation for serving on scientific advisory boards, honoraria for consultancy and funding for travel from Biogen Inc; speaker honoraria from NovartisLF declared no competing interestsKAM receives postdoctoral research funding from the Swedish Research Council for Health, Working Life and Welfare.AG has received research support from Novartis.JH has received honoraria for serving on advisory boards for Biogen, Celgene, Sanofi, Merck KGaA, Novartis and Sandoz and speaker’s fees from Biogen, Novartis, Merck KGaA, Teva and Sanofi. He has served as P.I. for projects, or received unrestricted research support from, Biogen, Celgene, Merck KGaA, Novartis, Roche and Sanofi. His MS research was funded by the Swedish Research Council and the Swedish Brain foundation.

Keywords: multiple sclerosis, covid-19, rituximabb

Suggested Citation

Spelman, Tim and Forsberg, Lars and McKay, Kyla and Glaser, Anna and Hillert, Jan, Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS Registry. Available at SSRN: https://ssrn.com/abstract=3801769 or http://dx.doi.org/10.2139/ssrn.3801769

Tim Spelman (Contact Author)

Karolinska Institutet - Department of Clinical Neuroscience

Stockholm, 171 77
Sweden

Lars Forsberg

Swedish MS Registry - Department of Clinical Neuroscience

Kyla McKay

Karolinska Institutet

Granits väg 4
Section for Integrative Physiology
Solna, 17171
Sweden

Anna Glaser

Karolinska Institutet

Granits väg 4
Section for Integrative Physiology
Solna, Stockholm 17171
Sweden

Jan Hillert

Karolinska Institutet - Department of Clinical Neuroscience ( email )

Stockholm, 171 77
Sweden

Click here to go to TheLancet.com

Paper statistics

Abstract Views
763
Downloads
108
PlumX Metrics